Related Experiment Video
Updated: Jan 17, 2026
Isolation, Characterization, and Therapeutic Application of Extracellular Vesicles from Cultured Human Mesenchymal Stem Cells
Published on: September 23, 2022
Investigating the Therapeutic Efficacy of Quality-Controlled, miR-146a-5p-Enriched Small Extracellular Vesicles
Xin Wang1, Lingjiao Meng1, Qiuhong Wang1
1R&D Department, Shandong Qilu Cell Therapy Engineering Technology Co., Ltd., Gangyuan 6th Road, Licheng District, Ji'nan, Shandong, 250000, P. R. China.
Abstract:
Small extracellular vesicles derived from umbilical cord mesenchymal stem cells (UC-sEvs) may be used for the treatment of idiopathic pulmonary fibrosis (IPF) because of their ability to control inflammation and inhibit fibrosis. However, the lack of clarity regarding the treatment mechanism of IPF and the corresponding quality standards limit the clinical application of these small extracellular vesicles. Here, we established a good manufacturing practice (GMP) grade process for isolating UC-sEvs, and RNA-seq was performed to screen for potential therapeutic cargo in the product to confirm the therapeutic effect of nebulized UC-sEv agents against IPF. Functionally, UC-sEvs inhibited the pulmonary inflammatory response by regulating macrophage function, thereby suppressing the bleomycin toxicity-induced progression of fibrosis. Mechanistically, miR-146a-5p enrichment in UC-sEvs may be involved in alleviating bleomycin-induced IPF by targeting TRAF6/IRAK1 to negatively regulate inflammation. The proposed quality control strategy ensures the stability of the product across three batches, with RNA-seq analysis revealing highly similar miRNA expression profiles. The feasibility of using miR-146a-5p as a key therapeutic molecule has been validated. Finally, on the basis of the results of pharmacodynamics and key therapeutic molecule studies, we provided a detailed quality control standard for IPF therapy by nebulizing UC-sEv. These findings help understand how sEvs impact IPF and the possible consequences of their therapeutic usage and offer a quality standard reference.
Insights
Small extracellular vesicles (sEVs) from umbilical cord stem cells show potential for treating idiopathic pulmonary fibrosis (IPF). These UC-sEVs regulate inflammation and fibrosis, with miR-146a-5p identified as a key therapeutic molecule.
Area of Science:
- Biomedical Engineering
- Regenerative Medicine
- Pulmonary Medicine
Background:
- Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with limited treatment options.
- Small extracellular vesicles (sEVs) derived from umbilical cord mesenchymal stem cells (UC-sEVs) exhibit anti-inflammatory and anti-fibrotic properties, suggesting therapeutic potential for IPF.
- Current understanding of UC-sEVs' therapeutic mechanisms and standardized quality control for clinical application remains insufficient.
Purpose of the Study:
- To establish a Good Manufacturing Practice (GMP)-grade process for isolating UC-sEVs.
- To investigate the therapeutic effects and underlying mechanisms of nebulized UC-sEVs against bleomycin-induced IPF.
- To develop a quality control strategy and identify key therapeutic molecules for UC-sEV-based IPF therapy.
Main Methods:
- Established a GMP-grade isolation process for UC-sEVs.
- Utilized RNA sequencing (RNA-seq) to analyze the cargo of UC-sEVs and identify potential therapeutic molecules.
- Evaluated the efficacy of nebulized UC-sEVs in a bleomycin-induced IPF mouse model, assessing pulmonary inflammation and fibrosis.
- Investigated the molecular mechanism involving miR-146a-5p targeting TRAF6/IRAK1 signaling pathway.
Main Results:
- Nebulized UC-sEVs effectively inhibited pulmonary inflammation and suppressed fibrosis progression in the bleomycin-induced IPF model.
- UC-sEVs regulate macrophage function to exert their anti-inflammatory effects.
- RNA-seq identified miR-146a-5p as a key therapeutic molecule within UC-sEVs, which targets TRAF6/IRAK1 to reduce inflammation.
- A robust quality control strategy ensured batch-to-batch consistency of UC-sEVs, with stable miRNA expression profiles.
Conclusions:
- Nebulized UC-sEVs demonstrate significant therapeutic potential for IPF by modulating inflammatory responses and inhibiting fibrosis.
- miR-146a-5p is a critical therapeutic component of UC-sEVs for IPF treatment, acting via the TRAF6/IRAK1 pathway.
- The developed GMP-grade process and quality control standards provide a foundation for the clinical application of UC-sEVs in IPF therapy.
More Related Videos
09:34Preparation of Plasma Membrane Vesicles from Bone Marrow Mesenchymal Stem Cells for Potential Cytoplasm Replacement Therapy
Published on: May 18, 2017
09:18Isolation of Extracellular Vesicles from Murine Bronchoalveolar Lavage Fluid Using an Ultrafiltration Centrifugation Technique
Published on: November 9, 2018
